MRS2500 tetraammonium,99.85%
产品编号:Bellancom-108658| CAS NO:630103-23-0| 分子式:C13H30IN9O8P2| 分子量:629.28
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
MRS2500 tetraammonium
产品介绍 | MRS2500 tetraammonium 是一种高效、选择性和稳定的 P2Y1 受体拮抗剂 (Ki=0.78 nM)。MRS2500 tetraammonium 抑制 ADP 诱导的人血小板聚集,IC50 值为 0.95 nM。具有抗血栓活性。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity. | ||||||||||||||||
体外研究 |
MRS2500 tetraammonium inhibits platelet aggregation to 10 μM ADP with an IC50 of 0.95 nM in human washed platelets. MRS2500 tetraammonium inhibits platelet aggregation to 10μM ADP with an IC50 of 0.49 μM in human PRP[4]. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
MRS2500 (2 mg/kg; i.v.) decreases acute systemic thromboembolism through selective inhibition of the P2Y1 receptor. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
体内研究 |
MRS2500 (2 mg/kg; i.v.) decreases acute systemic thromboembolism through selective inhibition of the P2Y1 receptor. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
H2O : 50 mg/mL (79.46 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
-20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |
|